Bronchogen 20mg

The effect of Bronchogen, a tetrapeptide, was investigated on the bronchial epithelium and inflammatory activity in the lungs of rats with chronic obstructive pulmonary disease (COPD).

The results showed that bronchogen treatment normalized the cellular composition and profile of pro-inflammatory cytokines and enzymes in the bronchoalveolar space, resulting in decreased activity of neutrophilic inflammation in the lungs.

Additionally, the structure of the bronchial epithelium, which was disturbed in the COPD model, was restored, accompanied by an increase in secretory immunoglobulin A and surfactant protein B, markers for local immunity and reducing alveolar surface tension, respectively.

THE PRODUCTS PURCHASED ON THIS WEBSITE ARE INTENDED FOR RESEARCH CHEMICAL USE ONLY. 

These products are not intended to be used for human or animal consumption and/or ingestion of any kind. 

These products should not be used as food additives, drugs or household chemicals.

These products should only be used by Qualified Professionals.

Bodily introduction into Human and Animals of any kind is strictly forbidden by law.

All the product information on this website is for educational purpose only.